Has Bayer recently launched a new insulin?

The landlord is well informed and does have some money to go public. Bayer will launch a new human insulin-Zhonghelin in the near future. Chonghelin (recombinant human insulin) is a kind of insulin which is completely consistent with human insulin structure, and is biosynthesized by genetic engineering technology with Escherichia coli as the host. Chonghelin's production is completely carried out under the EU GMP standard, and it is the most stringent drug production and quality management system in the world. Compared with the standard of China Pharmacopoeia, its index control is stricter. The production technology of Zhonghelin has two patents in 58 countries, including the United States, the European Union and China.